Methotrexate-associated alterations of the folate and methyl-transfer pathway in the CSF of all patients with and without symptoms of neurotoxicity

Pediatric Blood and Cancer

Volumn 52, Issue 1, 2009, Pages 26-32

  Vezmar, Sandra ^a   Schüsseler, Patrick ^a   Becker, Achim ^a   Bode, Udo ^a   Jaehde, Ulrich ^a  

^a UNIVERSITY OF BONN   (Germany)

Author keywords

5 methyltetrahydrofolate; CSF; Methotrexate; Neurotoxicity; S adenosylmethionine

Indexed keywords

5 METHYLTETRAHYDROFOLIC ACID; FOLIC ACID; FOLINATE CALCIUM; METHOTREXATE; S ADENOSYLHOMOCYSTEINE; S ADENOSYLMETHIONINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; AGITATION; ARTICLE; ATAXIA; BRAIN ISCHEMIA; CEREBROSPINAL FLUID; CHILD; CLINICAL ARTICLE; CRANIAL NEUROPATHY; DIZZINESS; DRUG MEGADOSE; FLUORESCENCE ANALYSIS; HEADACHE; HEMIPARESIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN TISSUE; IRRITABILITY; LUMBAR PUNCTURE; MALE; MOOD CHANGE; MOTOR NEUROPATHY; NEUROTOXICITY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REFLEX; SIDE EFFECT; SPEECH DISORDER; TREATMENT DURATION; TREMOR; ULTRAVIOLET SPECTROSCOPY; DRUG EFFECT; FEMALE; METABOLISM; METHYLATION; PRESCHOOL CHILD; TOXICITY AND INTOXICATION;

ADOLESCENT; CEREBROSPINAL FLUID; CHILD; CHILD, PRESCHOOL; FEMALE; FOLIC ACID; HUMANS; MALE; METABOLIC NETWORKS AND PATHWAYS; METHOTREXATE; METHYLATION; NEUROTOXICITY SYNDROMES; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA;

EID: 58149381703     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.21827     Document Type: Article

References (42)

1. Allen JC, Rosen G. Transient cerebral dysfunction following chemotherapy for osteogenic sarcoma. Ann Neurol 1978;3:441-444.
2. Allen JC, Rosen G, Mehta BM, Horten B. Leukoencephalopathy following high-dose iv methotrexate chemotherapy with leucovorin rescue. Cancer Treat Rep 1980;64:1261-1273.
3. Colamaria V, Caraballo R, Borgna-Pignatti C, et al. Transient focal leukoencephalopathy following intraventricular methotrexate and cytarabine. A complication of the Ommaya reservoir: Case report and review of the literature. Childs Nerv Syst 1990;6:231-235.
4. Bleyer WA. Neurologic sequelae of methotrexate and ionizing radiation: A new classification. Cancer Treat Rep 1981;65: Suppl 1 89-98.
5. Quinn CT, Kamen BA. A biochemical perspective of methotrexate neurotoxicity with insight on nonfolate rescue modalities. J Investig Med 1996;44:522-530.
6. Vezmar S, Becker A, Bode U, Jaehde U. Biochemical and clinical aspects of methotrexate neurotoxicity. Chemotherapy 2003;49:92-104.
7. Brock S, Jennings HR. Fatal acute encephalomyelitis after a single dose of intrathecal methotrexate. Pharmacotherapy 2004;24:673-676.
8. Walker RW, Allen JC, Rosen G, Caparros B. Transient cerebral dysfunction secondary to high-dose methotrexate. J Clin Oncol 1986;4:1845-1850.
9. Yim YS, Mahoney DH, Jr., Oshman DG. Hemiparesis and ischemic changes of the white matter after intrathecal therapy for children with acute lymphocytic leukemia. Cancer 1991;67:2058-2061.
10. Asato R, Akiyama Y, Ito M, et al. Nuclear magnetic resonance abnormalities of the cerebral white matter in children with acute lymphoblastic leukemia and malignant lymphoma during and after central nervous system prophylactic treatment with intrathecal methotrexate. Cancer 1992;70:1997-2004.
11. Packer RJ, Grossman RI, Belasco JB. High dose systemic methotrexate-associated acute neurologic dysfunction. Med Pediatr Oncol 1983;11:159-161.
12. Colosimo C, Di Lella GM, Petrone AM, et al. CNS radio-chemoprophylaxis in children with acute lymphoblastic leukemia. Neurotoxicity and diagnostic imaging. Rays 1994;19:511-526.
13. Ochs J, Mulhern R, Fairclough D, et al. Comparison of neuropsychologic functioning and clinical indicators of neurotoxicity in long-term survivors of childhood leukemia given cranial radiation or parenteral methotrexate: Aprospective study. J Clin Oncol 1991;9:145-151.
14. Paakko E, Harila-Saari A, Vanionpaa L, et al. White matter changes on MRI during treatment in children with acute lymphoblastic leukemia: Correlation with neuropsychological findings. Med Pediatr Oncol 2000;35:456-461.
15. Jacobs SA, Adamson RH, Chabner BA, et al. Stoichiometric inhibition of mammalian dihydrofolate reductase by the gamma-glutamyl metabolite of methotrexate, 4-amino-4-deoxy-N-10-methylpteroylglutamyl-gamma-glutamate. Biochem Biophys Res Commun 1975;63:692-698.
16. Jolivet J, Chabner BA. Intracellular pharmacokinetics of methotrexate polyglutamates in human breast cancer cells. Selective retention and less dissociable binding of 4-NH2-10-CH3-pteroylglutamate4 and 4-NH2-10-CH3- pteroylglutamate5 to dihydrofolate reductase. J Clin Invest 1983;72:773-778.
17. Cantoni GL. Biological methylation: Selected aspects. Annu Rev Biochem 1975;44:435-451.
18. Hirata F, Axelrod J. Phospholipid methylation and biological signal transmission. Science 1980;209:1082-1090.
19. Barber JR, Clarke S. Inhibition of protein carboxyl methylation by S-adenosyl-L-homocysteine in intact erythrocytes. J Biol Chem 1984;259:7115-7122.
20. Zappia V, Zydek-Cwick CR, Schlenk F. The specificity of S-adenosylmethionine derivatives in methyltransfer reactions. J Biol Chem 1969;244:4499-4505.
21. Allegra CJ, Fine RL, Drake JC, Chabner BA. The effect of methotrexate on intracellular folate pools in human MCF-7 breast cancer cells. Evidence for direct inhibition of purine synthesis. J Biol Chem 1986;261:6478-6485.
22. Allegra CJ, Hoang K, Yeh GC, et al. Evidence for direct inhibition of de novo purine synthesis in human MCF-7 breast cancer cells as a principal mode of metabolic inhibition by methotrexate. J Biol Chem 1987;262:13520-13526.
23. Abelson HT. Methotrexate and central nervous system toxicity. Cancer Treat Rep 1978;62:1999-2001.
24. Quinn CT, Griener JC, Bottiglieri T, et al. Elevation of homocysteine and excitatory amino acid neurotransmitters in the CSF of children who receive methotrexate for the treatment of cancer. J Clin Oncol 1997;15:2800-2806.
25. Quinn CT, Griener JC, Bottiglieri T, Kamen BA. Methotrexate, homocysteine, and seizures. J Clin Oncol 1998;16:393-394.
26. Quinn CT, Griener JC, Bottiglieri T, et al. Effects of intraventricular methotrexate on folate, adenosine, and homocysteine metabolism in cerebrospinal fluid. J Pediatr Hematol Oncol 2004;26:386-388.
27. Ramaekers VT, Häusler M, Opladen T, et al. Psychomotor retardation, spastic paraplegia, cerebellar ataxia, and dyskinesia associated with low 5-methyltetrahydrofolate in cerebrospinal fluid: A novel neurometabolic condition responding to folinic acid substitution. Neuropediatrics 2002;33:301-308.
28. Hyland K, Smith I, Bottiglieri T, et al. Demyelination and decreased S-adenosylmethionine in 5,10-methylenetetrahydrofolate reductase deficiency. Neurology 1988;38:459-462.
29. Surtees R, Leonard J, Austin S. Association of demyelination with deficiency of cerebrospinal-fluid S-adenosylmethionine in inborn errors of methyl-transfer pathway. Lancet 1991;338:1550-1554.
30. Kishi T, Tanaka Y, Ueda K. Evidence for hypomethylation in two children with acute lymphoblastic leukemia and leukoencephalopathy. Cancer 2000;89:925-931.
31. Belz S, Frickel C, Wolfrom C, et al. High-performance liquid chromatographic determination of methotrexate, 7-hydroxymethotrexate, 5-methyltetrahydrofolic acid and folinic acid in serum and cerebrospinal fluid. J Chromatogr B 1994;661:109-118.
32. US Department of Health and Human Services, and Food and Drug Administration. Guidance for industry: Bioanalytical method validation, 2001.
33. Wagner J, Hirth Y, Claverie N, Danzin CA. Sensitive high-performance liquid chromatographic procedure with fluorometric detection for the analysis of decarboxylated S-adenosylmethionine and analogs in urine samples. Anal Biochem 1986;154:604-617.
34. Thyss A, Milano G, Etienne MC, et al. Evidence for CSF accumulation of 5-methyltetrahydrofolate during repeated courses of methotrexate plus folinic acid rescue. Br J Cancer 1989;59:627-630.
35. Surtees R, Hyland K. Cerebrospinal fluid concentrations of S-adenosylmethionine, methionine, and 5-methyltetrahydrofolate in a reference population: Cerebrospinal fluid S-adenosylmethionine declines with age in humans. Biochem Med Metab Biol 1990;44:192-199.
36. Mehta BM, Glass JP, Shapiro WR. Serum and cerebrospinal fluid distribution of 5-methyltetrahydrofolate after intravenous calcium leucovorin and intra-Ommaya methotrexate administration in patients with meningeal carcinomatosis. Cancer Res 1983;43:435-438.
37. Reggev A, Djerassi I. Rescue from high-dose methotrexate with 5-methyltetrahydrofolate. Cancer Treat Rep 1986;70:251-253.
38. Struys EA, Jansen EEW, de Meer K, Jakobs C. Determination of S-adenosylmethionine and S-adenosylhomocysteine in plasma and cerebrospinal fluid by stable-isotope dilution tandem mass spectrometry. Clin Chem 2002;46:1650-1661.
39. Weir DG, Molloy AM, Keating JN, et al. Correlation of the ratio of S-adenosyl-L-methionine to S-adenosyl-L-homocysteine in the brain and cerebrospinal fluid of the pig: Implications for the determination of this methylation ratio in human brain. Clin Sci (Lond) 1992;82:93-97.
40. Haykin M, Gorman M, van Hoff J, et al. Diffusion-weighted MRI correlates of subacute methotrexate-related neurotoxicity. J Neurooncol 2006;76:153-157.
41. Kuker W, Bader P, Herrlinger U, et al. Transient encephalopathy after intrathekal methotrexate chemotherapy: Diffusion-weighted MRI. J Neurooncol 2005;73:47-49.
42. Surtees R, Clelland J, Hann I. Demyelination and single-carbon transfer pathway metabolites during the treatment of acute lymphoblastic leukemia: CSF studies. J Clin Oncol 1998;16:1505-1511.